SNU-398

SNU-398/SNU-398细胞系/SNU-398细胞株/SNU-398人肝癌细胞

Cell line name SNU-398

Synonyms SNU398; NCI-SNU-398

Accession CVCL_0077

Resource Identification Initiative To cite this cell line use: SNU-398 (RRID:CVCL_0077)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: Liver Cancer Model Repository (LIMORE).

Part of: MD Anderson Cell Lines Project.

Part of: Seoul National University (SNU) cell line collection.

Population: Korean.

Doubling time: 39 hours (PubMed=7543080); 25.49 hours (PubMed=31378681).

Karyotypic information: Has lost chromosome Y.

Microsatellite instability: Stable (MSS) (Sanger).

Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: miRNA expression profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Liver; UBERON=UBERON_0002107.

Source(s): ATCC=CRL-2233; Cosmic-CLP=1240217; KCLB=00398; PubMed=25877200; PubMed=31378681

 

Markers:

Amelogenin X,Y

CSF1PO 13

D2S1338 19

D3S1358 17

D5S818 12

D7S820 10,11

D8S1179 12

D13S317 11

D16S539 10,14

D18S51 15 (PubMed=25877200)

15,19 (ATCC=CRL-2233)

D19S433 14,14.1

D21S11 29

FGA 22,23 (KCLB=00398)

23 (ATCC=CRL-2233; PubMed=25877200)

Penta D 14

Penta E 12

TH01 7,9 (ATCC=CRL-2233; Cosmic-CLP=1240217; PubMed=25877200)

8,9 (KCLB=00398)

9 (PubMed=31378681)

TPOX 11

vWA 17,18

 

Run an STR similarity search on this cell line

Publications

PubMed=7543080; DOI=10.1002/ijc.2910620308

Park J.-G., Lee J.-H., Kang M.-S., Park K.-J., Jeon Y.-M., Lee H.-J., Kwon H.-S., Park H.-S., Yeo K.-S., Lee K.-U., Kim S.-T., Chung J.-K., Hwang Y.-J., Lee H.-S., Kim C.Y., Lee Y.I., Chen T.-R., Hay R.J., Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.

Characterization of cell lines established from human hepatocellular carcinoma.

Int. J. Cancer 62:276-282(1995)

 

PubMed=8824565; DOI=10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X

Kang M.-S., Lee H.-J., Lee J.-H., Ku J.-L., Lee K.P., Kelley M.J., Won Y.-J., Kim S.-T., Park J.-G.

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

Int. J. Cancer 67:898-902(1996)

 

PubMed=19956504; DOI=10.4143/crt.2005.37.1.1; PMCID=PMC2785416

Ku J.-L., Park J.-G.

Biology of SNU cell lines.

Cancer Res. Treat. 37:1-19(2005)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=23505090; DOI=10.1002/hep.26402

Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z., Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.-C.

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Hepatology 58:706-717(2013)

 

PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665

Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Nat. Commun. 4:2218.1-2218.7(2013)

 

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

 

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311; PMCID=PMC4284350

Cevik D., Yildiz G., Ozturk M.

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

World J. Gastroenterol. 21:311-317(2015)

 

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)